<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e>-specific variable regions of the clonal immunoglobulin (idiotype, Id) expressed by B cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) can be targeted by active immunotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a phase I/II trial to determine the safety and immunogenicity of a patient-specific, recombinant, mammalian cell-derived Id protein conjugated to keyhole limpet hemocyanin (Id-KLH; MyVax personalised immunotherapy) in 22 patients with follicular NHL in first remission after chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Subjects received five subcutaneous immunisations with MyVax plus locally administered granulocyte-macrophage colony-stimulating factor (GM-CSF) </plain></SENT>
<SENT sid="3" pm="."><plain>Among 21 evaluable patients, 62% mounted Id-specific immune responses </plain></SENT>
<SENT sid="4" pm="."><plain>Evoked anti-Id antibodies recognised both recombinant Id and native Id, and could specifically stain autologous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>At median follow-up of more than 6 years, median progression-free survival is 38 months </plain></SENT>
<SENT sid="6" pm="."><plain>Immunisation of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients with MyVax Id-KLH is safe and patients often mount <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific immune responses </plain></SENT>
<SENT sid="7" pm="."><plain>These results form the basis of a pivotal phase 3 trial of MyVax in follicular NHL </plain></SENT>
</text></document>